Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

BLISS-52 and BLISS-76, the ongoing Phase 3 trials of LymphoStat-B (belimumab), are the largest clinical trials ever conducted in lupus patients. HGS expects to report the first Phase 3 data for LymphoStat-B in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Darapladib: GSK Initiates Phase 3 Development Program

In December 2008, GSK initiated STABILITY, the first Phase 3 clinical trial to evaluate the efficacy and safety of treatment with the investigational Lp-PLA2 inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary heart disease. More than 15,000 patients will participate in STABILITY. Darapladib was discovered by GSK based on HGS technology. HGS will receive 10% royalties on worldwide sales if darapladib is commercialized, and has a 20% co-promotion option in North America and Europe.

Syncria(R): GSK Initiates Phase 3 Development; HGS to Receive $9 Million Milestone

In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $24 million received to date and an additional $9 million milestone payment to be received in the first quarter of 2009. HGS is also entitled to single-digit royalties on worldwide sales if Syncria is commercialized.

CONFERENCE CALL

HGS management
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research and ... "Surgical Incision Closures - Global Strategic Business Report" ... comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America ... the worldwide markets for Surgical Incision Closures in US$ Million ...
(Date:6/2/2015)... , June 2, 2015 Intarcia Therapeutics, ... $75 million from its recently announced synthetic royalty / ... $300 million. Investors have purchased Convertible Limited Recourse Notes ... equal to 2.0% of any future global net sales ... fully paid. Investors also have the option, commencing upon ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Surgical Incision Closures - Global Strategic Business Report 2015 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
(Date:6/2/2015)... Long Island, N.Y. (PRWEB) June 02, 2015 ... to refer to computer generated imagery overlaid on the ... and gone but Vein Visualization, which displays a map ... has shown a steady growth in adoption. , AccuVein, ... a 40% year over year growth rate and such ...
(Date:6/2/2015)... “ Radaris ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers can ... person. , According to Psychology Today, humans are a curious ... that curiosity is a part of human development. People are ...
(Date:6/2/2015)... FL (PRWEB) June 02, 2015 MedPro ... staffing services to healthcare facilities, today announced the worldwide ... and effective mobile tool to help candidates find best ... Glassdoor survey released in 2014, 9 in 10 job ... during their job search. , The MedPro Top Jobs ...
(Date:6/2/2015)... OR (PRWEB) June 02, 2015 ZOOM+, ... of ZOOM+ Performance Health Insurance, announced today the opening ... Clean White 57 - a three-in-one complete dental exam, ... Clean Jr. for kids. Like all ZOOM+ services, ZOOM+Smile ... , “Why shouldn’t the dentist office be as inviting ...
(Date:6/2/2015)... DiaTech Oncology, provider of CorrectChemo®, the ... help oncologists provide personalized cancer treatment, has gained ... for its laboratories in the U.S. and Canada. ... the ‘Good Housekeeping’ seal of approval,” says Robert ... DiaTech. “It’s a rigorous inspection that confirms our ...
Breaking Medicine News(10 mins):Health News:Vein Visualization Emerges as Premier Augmented Reality Application 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:MedPro Healthcare Staffing Launches New MedPro Top Jobs App To Facilitate Job Search For Healthcare Professionals 2Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2
... the University of Wisconsin-Madison have identified dozens of clues ... ,The researchers identified nearly 40 genes that, ... the parasite from forming an infection in the brains ... of promising targets for developing drugs that could block ...
... brand ambassadors of India. But they could also prove a ... case of Thirumurthy Nakka Boomaiah , 35 and hailing ... ,He has been sentenced to 69 days in ... London to Philadelphia and assaulting flight attendants. But he has ...
... Michigan patients will have a new -- virtually pain ... Joseph Mercy Health System (SJMHS) announced today it will ... System on Wednesday, June 6th. ,This advanced ... body, including previously inoperable tumors, with astounding accuracy and ...
... The Seattle-based Infectious Disease Research Institute (IDRI) and ... entered into two research and development agreements ... Leishmaniasis and Leprosy, two 'neglected diseases' targeted by ... using Chembio's patented Dual Path immunoassay test platform ...
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... A psychologist at the University College London has designed a ... can be distracted. ,Professor Nilli Lavie claims that ... tool during the recruitment process, and may be beneficial in ... ,"When you are easily distracted, you are more liable ...
Cached Medicine News:Health News:Mutant Parasites, Unable to Infect Hosts, Highlight Virulence Genes 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2Health News:IDRI and Chembio to Develop Tests for Leishmaniasis and Leprosy 2Health News:IDRI and Chembio to Develop Tests for Leishmaniasis and Leprosy 3Health News:Individuals Distraction can Be Measured by a Computer Based Test 2
... Wireless, internet-based ... provides compliance and ... complete system. The ... System incorporates communication ...
GelPort hand access laparoscopy combines the patient outcomes of minimally invasive surgery with the speed and precision of open surgery....
The CPAP TREND 110 delivers performance with quiet operation. Can be used together with the SomnoPlus CPAP Mask and AquaTrend Heated Humidifier....
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
Medicine Products: